Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Prospective study on breastfeeding, lipid profile and cardiovascular risk markers in women with familial hypercholesterolaemia: study protocol for the FH-FEMINA study

M. Klevmoen, JWCM. Mulder, MP. Bogsrud, K. Retterstøl, EK. Vesterbekkmo, EKR. Pedersen, T. Freiberger, M. Vrablik, M. Vaclova, A. Hovland, NT. Vethe, HK. Brekke, PO. Iversen, M. Veierød, J. Roeters van Lennep, KB. Holven

. 2025 ; 15 (4) : e092208. [pub] 20250427

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, protokol klinické studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25016036

INTRODUCTION: Early and lifelong treatment is essential in patients with familial hypercholesterolaemia (FH) due to genetically elevated low-density lipoprotein cholesterol (LDL-C) from the first years of life. In women with FH, lipid-lowering treatment is interrupted during childbearing years due to contraindication of the medication during conception, pregnancy and breastfeeding. However, little is known about the impact of breastfeeding on lipid profile and other risk markers for atherosclerotic cardiovascular disease (ASCVD) in women with FH compared with women without hypercholesterolaemia, and to what extent statins transfer into breast milk.We aim to investigate (1) the association between breastfeeding and serum lipid profile in women with and without FH; (2) the association between breastfeeding and other ASCVD risk markers in women with and without FH and (3) the concentration of statins in breast milk of women with FH. METHODS AND ANALYSIS: FH-FEMINA is a prospective study aiming to include 50 women with FH in Norway, the Netherlands and the Czech Republic. Additionally, 20 women without hypercholesterolaemia will be enrolled as a control group in Norway. Women will be included at the first study visit in gestational week 36, and follow-up visits will be scheduled at 2-4 weeks, and at 3, 6, 9 and 12 months postpartum. Information on lifestyle factors, treatment history and current and previous pregnancies will be collected. At each visit, a non-fasting blood sample, breast milk sample and information on diet, body mass index and blood pressure will be collected. Additional blood samples will be collected from the women with FH at 2, 4, 5, 7, 8, 10 and 11 months postpartum for as long as they are breastfeeding. At (re-)initiation of statin treatment, breast milk samples from women with FH will be collected for drug concentration measurements. ETHICS AND DISSEMINATION: Ethical approval will be obtained prior to study start in all three countries. Participants will be informed about the study and receive ample time to ask questions before the informed consent form is signed. The findings from this study will be disseminated to healthcare professionals, researchers and patients via peer-reviewed scientific article(s), conferences, patient organisations and social media. TRIAL REGISTRATION NUMBER: NCT05367310.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25016036
003      
CZ-PrNML
005      
20250731091446.0
007      
ta
008      
250708s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/bmjopen-2024-092208 $2 doi
035    __
$a (PubMed)40288796
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Klevmoen, Marianne $u Norwegian National Advisory Unit on Familial Hypercholesterolemia, Oslo University Hospital, Oslo, Norway $u Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway
245    10
$a Prospective study on breastfeeding, lipid profile and cardiovascular risk markers in women with familial hypercholesterolaemia: study protocol for the FH-FEMINA study / $c M. Klevmoen, JWCM. Mulder, MP. Bogsrud, K. Retterstøl, EK. Vesterbekkmo, EKR. Pedersen, T. Freiberger, M. Vrablik, M. Vaclova, A. Hovland, NT. Vethe, HK. Brekke, PO. Iversen, M. Veierød, J. Roeters van Lennep, KB. Holven
520    9_
$a INTRODUCTION: Early and lifelong treatment is essential in patients with familial hypercholesterolaemia (FH) due to genetically elevated low-density lipoprotein cholesterol (LDL-C) from the first years of life. In women with FH, lipid-lowering treatment is interrupted during childbearing years due to contraindication of the medication during conception, pregnancy and breastfeeding. However, little is known about the impact of breastfeeding on lipid profile and other risk markers for atherosclerotic cardiovascular disease (ASCVD) in women with FH compared with women without hypercholesterolaemia, and to what extent statins transfer into breast milk.We aim to investigate (1) the association between breastfeeding and serum lipid profile in women with and without FH; (2) the association between breastfeeding and other ASCVD risk markers in women with and without FH and (3) the concentration of statins in breast milk of women with FH. METHODS AND ANALYSIS: FH-FEMINA is a prospective study aiming to include 50 women with FH in Norway, the Netherlands and the Czech Republic. Additionally, 20 women without hypercholesterolaemia will be enrolled as a control group in Norway. Women will be included at the first study visit in gestational week 36, and follow-up visits will be scheduled at 2-4 weeks, and at 3, 6, 9 and 12 months postpartum. Information on lifestyle factors, treatment history and current and previous pregnancies will be collected. At each visit, a non-fasting blood sample, breast milk sample and information on diet, body mass index and blood pressure will be collected. Additional blood samples will be collected from the women with FH at 2, 4, 5, 7, 8, 10 and 11 months postpartum for as long as they are breastfeeding. At (re-)initiation of statin treatment, breast milk samples from women with FH will be collected for drug concentration measurements. ETHICS AND DISSEMINATION: Ethical approval will be obtained prior to study start in all three countries. Participants will be informed about the study and receive ample time to ask questions before the informed consent form is signed. The findings from this study will be disseminated to healthcare professionals, researchers and patients via peer-reviewed scientific article(s), conferences, patient organisations and social media. TRIAL REGISTRATION NUMBER: NCT05367310.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    12
$a kojení $7 D001942
650    12
$a hyperlipoproteinemie typ II $x krev $x farmakoterapie $x komplikace $7 D006938
650    _2
$a prospektivní studie $7 D011446
650    12
$a mateřské mléko $x chemie $x metabolismus $7 D008895
650    _2
$a dospělí $7 D000328
650    _2
$a biologické markery $x krev $7 D015415
650    12
$a statiny $x terapeutické užití $7 D019161
650    _2
$a rizikové faktory kardiovaskulárních chorob $7 D000082742
650    12
$a kardiovaskulární nemoci $7 D002318
650    12
$a lipidy $x krev $7 D008055
651    _2
$a Nizozemsko $7 D009426
651    _2
$a Česká republika $7 D018153
651    _2
$a Norsko $7 D009664
655    _2
$a časopisecké články $7 D016428
655    _2
$a protokol klinické studie $7 D000078325
700    1_
$a Mulder, Janneke W C M $u Department of Internal Medicine, Erasmus MC Cardiovascular Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands $1 https://orcid.org/000900039837726X
700    1_
$a Bogsrud, Martin P $u Unit for Cardiac and Cardiovascular Genetics, Oslo University Hospital, Oslo, Norway
700    1_
$a Retterstøl, Kjetil $u Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway $u The Lipid Clinic, Oslo University Hospital, Oslo, Norway $1 https://orcid.org/0000000213097556
700    1_
$a Vesterbekkmo, Elisabeth K $u Clinic of Cardiology, St. Olavs University Hospital, Trondheim, Norway
700    1_
$a Pedersen, Eva K R $u Department of Heart Disease, Haukeland University Hospital, Bergen, Norway $u Department of Clinical Science, University of Bergen, Bergen, Norway
700    1_
$a Freiberger, Tomas $u Centre of Cardiovascular Surgery and Transplantation, Brno, Czech Republic $u Medical Faculty, Masaryk University, Brno, Czech Republic $u National Institute for Metabolic and Cardiovascular Disease Research, Brno, Czech Republic
700    1_
$a Vrablik, Michal $u Third Department of Internal Medicine, General University Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Vaclova, Martina $u National Institute for Metabolic and Cardiovascular Disease Research, Brno, Czech Republic $u Third Department of Internal Medicine, General University Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Hovland, Anders $u Nordland Heart Center, Bodo, Norway $1 https://orcid.org/0000000339796627
700    1_
$a Vethe, Nils Tore $u Department of Pharmacology, Oslo University Hospital, Oslo, Norway $u Department of Pharmacy, University of Oslo, Oslo, Norway
700    1_
$a Brekke, Hilde Kristin $u Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway
700    1_
$a Iversen, Per Ole $u Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway $u Department of Haematology, Oslo University Hospital, Oslo, Norway
700    1_
$a Veierød, Marit $u Oslo Centre of Biostatistics and Epidemiology, Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway
700    1_
$a Roeters van Lennep, Jeanine $u Department of Internal Medicine, Erasmus MC Cardiovascular Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands $1 https://orcid.org/0000000168709962
700    1_
$a Holven, Kirsten B $u Norwegian National Advisory Unit on Familial Hypercholesterolemia, Oslo University Hospital, Oslo, Norway kirsten.holven@medisin.uio.no $u Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway $1 https://orcid.org/0000000286749703
773    0_
$w MED00184484 $t BMJ open $x 2044-6055 $g Roč. 15, č. 4 (2025), s. e092208
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40288796 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091440 $b ABA008
999    __
$a ok $b bmc $g 2366708 $s 1253161
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 15 $c 4 $d e092208 $e 20250427 $i 2044-6055 $m BMJ open $n BMJ Open $x MED00184484
LZP    __
$a Pubmed-20250708
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace